Literature DB >> 20871594

The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls.

Karishma K Mehra1, Martin C Chang, Ann K Folkins, Caroline J Raho, Joema F Lima, Liping Yuan, Mitra Mehrad, Shelley S Tworoger, Christopher P Crum, Aasia Saleemuddin.   

Abstract

The tubal p53 signature is a putative precursor to pelvic serous carcinoma, but its frequencies in women with inherited mutations in the BRCA1 or BRCA2 genes (BRCA+) and controls has been controversial. An initial section and two levels (100-200 μm) from every block in BRCA+ (24) and control tubes (40) were stained for p53. The frequency of p53 signatures was computed between the populations and across the three levels from each block, and analyzed by Fisher exact test. A total of 17 (71%) BRCA+ and 20 (50%) control tubes were p53 signature positive (P=0.12); 21 and 16% of all tissue blocks sectioned harbored signatures (P=0.29), and 76 and 67% were found in the fimbria. In 49 and 32% of p53 signature positive cases in the two groups, the p53 signatures were not discovered until the second or third round of sectioning. In all, 38 and 40% of BRCA+ and control subjects harbored p53 signatures in more than one focus in a single block. In one case (BRCA+), a highly atypical proliferation was identified in one serial section. The p53 signatures are more common than previously reported and the frequency of detection increases as a function of sectioning through the tissue block, both in absolute frequency and in numbers of p53 signatures detected in a given block. There is a trend for a higher absolute frequency of p53 signatures (71 vs 50%; P=0.12) in BRCA+ subjects, but this is not reflected in a greater average number of p53 signatures or positive blocks per case. This study underscores the importance of systematic immunohistochemical examination of fallopian tubes when conducting epidemiological studies that compare the frequency of p53 signatures in different populations. Attention to this detail is critical when exploring risk factors germane to early serous carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20871594     DOI: 10.1038/modpathol.2010.171

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.

Authors:  Eleanor Y Chen; Karishma Mehra; Mitra Mehrad; Gang Ning; Alexander Miron; George L Mutter; Nicholas Monte; Bradley J Quade; Frank D McKeon; Yosuf Yassin; Wa Xian; Christopher P Crum
Journal:  J Pathol       Date:  2010-09       Impact factor: 7.996

Review 2.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

3.  Three-dimensional modeling of the human fallopian tube fimbriae.

Authors:  Sharon L Eddie; Suzanne M Quartuccio; Jie Zhu; Jessica A Shepherd; Rajul Kothari; J Julie Kim; Teresa K Woodruff; Joanna E Burdette
Journal:  Gynecol Oncol       Date:  2014-12-16       Impact factor: 5.482

4.  Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.

Authors:  Mary C Tolcher; Elizabeth M Swisher; Fabiola Medeiros; Joema F Lima; Jodi L Hilderbrand; Janis L Donovan; Rochelle L Garcia; William A Cliby; Sean C Dowdy
Journal:  Int J Gynecol Pathol       Date:  2015-01       Impact factor: 2.762

Review 5.  Advancements in Microfluidic Systems for the Study of Female Reproductive Biology.

Authors:  Vedant V Bodke; Joanna E Burdette
Journal:  Endocrinology       Date:  2021-10-01       Impact factor: 4.736

Review 6.  Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.

Authors:  Isao Otsuka
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

7.  TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.

Authors:  Tomoko Akahane; Kenta Masuda; Akira Hirasawa; Yusuke Kobayashi; Arisa Ueki; Miho Kawaida; Kumiko Misu; Kohei Nakamura; Shimpei Nagai; Tatsuyuki Chiyoda; Wataru Yamagami; Shigenori Hayashi; Fumio Kataoka; Kouji Banno; Kokichi Sugano; Hajime Okita; Kenjiro Kosaki; Hiroshi Nishihara; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2022-03-21       Impact factor: 4.756

8.  Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy.

Authors:  Hao Chen; Robert Klein; Stacy Arnold; Setsuko Chambers; Wenxin Zheng
Journal:  Cancer Cell Int       Date:  2016-10-01       Impact factor: 5.722

9.  Biomarkers and Strategies for Early Detection of Ovarian Cancer.

Authors:  Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-13       Impact factor: 4.254

Review 10.  Early preinvasive lesions in ovarian cancer.

Authors:  Gautier Chene; Gery Lamblin; Karine Le Bail-Carval; Philippe Chabert; Naoual Bakrin; Georges Mellier
Journal:  Biomed Res Int       Date:  2014-04-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.